Pharmacology

Pharmacology is the study of how chemical substances interact with living systems. If substances have medicinal properties, they are considered pharmaceuticals. The field encompasses drug composition and properties, interactions, toxicology, therapy, and medical applications and antipathogenic capabilities.

Pharmacology

Pharmacology is the study of the action of drugs on a biologic system. It incorporates components of medicine and biology, and how they interact with each other.

What is in Silico?

What is Drug Absorption?

Drug Distribution

Drug Excretion / Elimination

Drug Metabolism

Pharmacokinetics

What is Psychopharmacology?

Psychopharmacology and Neuropsychopharmacology Research

What is Pharmacoepidemiology?

What is Neuropharmacology?

Metabolomics in Pharmacology

See more featured articles »

Importance of Allostery in Pharmacology

Importance of Pharmacology in Dentistry

Pharmacist Career

What is Quantitative Systems Pharmacology (QSP) Modeling?

What is a Dose-Response Curve?

Latest Pharmacology News and Research

Novel drug molecule offers hope for early Parkinson's disease treatment

A novel drug molecule could potentially lead to new treatments to prevent Parkinson's disease in younger patients, according to new research.

20 Sep 2024

Study explores microglial response to chronic hyponatremia and rapid sodium correction

Low serum sodium concentrations in blood are called hyponatremia, a prevalent clinical electrolyte disorder.

18 Sep 2024

Study paves way for revolutionizing the management of muscle disorders

The type 1 ryanodine receptor (RyR1) is an important calcium release channel in skeletal muscles essential for muscle contraction.

18 Sep 2024

NIH funds study on environmental impact on male fertility

A grant from the National Institutes of Health will support ongoing research at Wayne State University investigating the consequences environmental factors may have on fertility in males.

18 Sep 2024

New insights into the mechanisms of efavirenz-induced neurotoxicity

Efavirenz is an important drug for treating HIV infection, but it has negative effects that can significantly impact patients' quality of life over time. It causes neuropsychiatric disorders and neurocognitive impairment in roughly 50 percent of patients. The drug is associated with abnormal lipid levels in blood plasma, but the molecular mechanisms responsible for negative clinical observations are unknown.

18 Sep 2024

Study highlights limited evidence for antidepressants in treating pain in older adults

University of Sydney research has found people over 65 are being prescribed antidepressants as pain treatment based on international guidelines that use limited evidence.

16 Sep 2024

Novel delivery platform enhances effectiveness of cancer immunotherapy and reduces side effects

Immunotherapy is a type of cancer treatment that uses the body's own immune system to help fight cancer. This is by stimulating the immune response to recognize and attack cancer cells more effectively.

16 Sep 2024

Study sheds light on potential demand for psilocybin-assisted therapy for depression in the U.S.

In the wake of mounting evidence for the efficacy of psychedelic-assisted therapies, the U.S. Food and Drug Administration (FDA) is considering approving psilocybin, the active ingredient in "magic mushrooms," for treating depression in the near future.

13 Sep 2024

Cannabidiol shows promise in treating cognitive disorders

Research reviews the therapeutic potential of cannabidiol (CBD) in treating cognitive impairments, highlighting positive effects in some trials while emphasizing the need for more comprehensive studies.

12 Sep 2024

New IndiPHARM initiative aims to revolutionize personalized medication management

A Columbia University-led multicenter research effort called IndiPHARM: individual metabolome and exposome assessment for pharmaceutical optimization will develop a platform and monitoring system to prevent unwanted interactions between medications and other environmental, genetic, and lifestyle factors, in order to optimize therapeutic efficacy.

12 Sep 2024

Zongertinib shows promising efficacy in HER2 mutation-positive NSCLC

The HER2-specific tyrosine kinase inhibitor zongertinib was well tolerated and demonstrated promising efficacy in patients with HER2 mutation-positive non-small cell lung cancer, meeting the primary endpoint of the Beamion LUNG-1 Phase Ib Cohort 1 study, according to research presented today at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer.

11 Sep 2024